Filing Flows › Veracyte (VCYT) › Q2 2026 › vs Q1 2026
Veracyte (VCYT) Q2 2026 vs Q1 2026 (quarter over quarter)
Veracyte's revenue rose $11.2M (+8%) from $139M in Q1 2026 to $150M in Q2 2026. The biggest changes: Testing revenue +$10.6M (+8%); Biopharmaceutical and other revenue +$501K (+166%); Product revenue +$179K (+5%). Gross margin 72.2% against 72.7% (-0.5 pts).
Veracyte, Q2 2026: revenue $150M (+16% year over year), operating margin 15.3%, net earnings $25.5M, operating cash flow $45.8M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Gross margin | 72.2% | 72.7% | -0.5 pts |
| Operating margin | 15.3% | 16.3% | -1.0 pts |
| Net margin | 17.0% | 20.6% | -3.7 pts |
| Free cash flow margin | 28.6% | 23.2% | +5.4 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Testing revenue | $146M | $135M | $10.6M | +8% |
| Product revenue | $3.9M | $3.7M | $179K | +5% |
| Biopharmaceutical and other revenue | $802K | $301K | $501K | +166% |
| Revenue | $150M | $139M | $11.2M | +8% |
| Gross profit | $109M | $101M | $7.4M | +7% |
| Cost of revenue | $41.8M | $37.9M | $3.9M | +10% |
| Other income, net | $3.5M | $7.3M | −$3.8M | -52% |
| Operating profit | $23.0M | $22.6M | $334K | +1% |
| Operating expenses | $85.6M | $78.5M | $7.1M | +9% |
| Pre-tax earnings | $26.5M | $30.0M | −$3.5M | -12% |
| Research & development | $29.4M | $27.1M | $2.3M | +9% |
| Sales & marketing | $28.3M | $27.2M | $1.1M | +4% |
| General & admin | $27.4M | $23.7M | $3.8M | +16% |
| Other operating costs | $421K | $579K | −$158K | -27% |
| Net earnings | $25.5M | $28.7M | −$3.2M | -11% |
| Income tax | $1.0M | $1.3M | −$234K | -18% |
| Depreciation & amortization | $4.8M | $5.4M | −$592K | -11% |
| Share-based compensation | $14.1M | $12.8M | $1.3M | +10% |
| Working capital & other | $1.4M | −$11.7M | $13.1M | — |
| Operating cash flow | $45.8M | $35.2M | $10.6M | +30% |
| Free cash flow (OCF − capex) | $43.0M | $32.3M | $10.7M | +33% |
| Capital expenditures | $2.9M | $3.0M | −$103K | -3% |
Questions
How much did Veracyte's revenue grow quarter over quarter in Q2 2026?
Veracyte's revenue rose $11.2M (+8%) from $139M in Q1 2026 to $150M in Q2 2026.
What drove Veracyte's revenue change in Q2 2026?
Testing revenue +$10.6M (+8%); Biopharmaceutical and other revenue +$501K (+166%); Product revenue +$179K (+5%).